New Retina Radio By Eyetube

This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again. Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography. This editorially independent podcast is supported with advertising.

New Retina Radio continues its biography of anti-VEGF. John D. Pitcher III, MD, picks up the story where we left off: in a world where pegaptanib was the only intravitreal injection approved for treating wet AMD. But a deep dive into the literature and a few calculations on the back of a napkin are about to change retina practice forever. Guests in this episode include Bob Avery, MD; Dave Brown, MD; Anne Fung, MD; Jeffrey Heier, MD; Andrew Moshfeghi, MD, MBA; Kirk Packo, MD; and Philip Rosenfeld, MD, PhD. This editorially independent podcast is supported with advertising.

Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

In this roundtable moderated by Allen C. Ho, MD, and Robert L. Avery, MD, experts discuss the frustration of postoperative proliferative vitreoretinopathy and strategies to minimize its incidence in the clinic.  Panelists include Dean Eliott, MD; Avni P. Finn, MD, MBA; Ajay Kuriyan, MD, MS; and M. Ali Khan, MD. This podcast is editorially independent.

Many young retina specialists have always known retina as an anti-VEGF world. But how did this happen? John D. Pitcher III, MD, joins Scott and Ranna in studio to deliver the first part of the tale of anti-VEGF in retina, taking the story back to the 1970s to tell the story of the discovery of VEGF, the creation of pegaptanib, and the struggles that early anti-VEGF encountered in retina. There are a lot of guests for this one, but the major players for this episode are Tony Adamis, MD; Bob Avery, MD; Jeff Heier, MD; and Kirk Packo, MD. This editorially independent podcast is supported with advertising.

Innovation often drives surgeons to adopt new techniques and surgical approaches. Join John Kitchens, MD, Carl Awh, MD, and Aleksandra Rachitskaya, MD as they discuss their experiences with a new refillable, intraocular device that enables continuous delivery of therapy for patients with nAMD. Listen as they provide their insights on learning the implant and refill- exchange procedures as well as their perspectives on the training program for the device. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

In the culmination of this case-based series discussing who is best suited for which types of wet AMD therapy, John Kitchens, MD, invites Murtaza Adam, MD, and Aleksandra Rachitskaya, MD, to the program to showcase two real-world patient files. After they are done with case discussions, Drs. Adam, Kitchens, and Rachitskaya examine how patient lifestyle details may affect treatment strategies.  This editorially independent podcast is supported with advertising.

In the second installment of this ongoing series covering wet AMD, Lisa Faia, MD, and Sumit Sharma, MD, submit to host John Kitchens, MD, a set of real-world patient cases in which treatment challenges necessitated a change in therapy. After revealing which treatment option is best suited for their respective patients, Drs. Faia and Sharma parse which patient types are eligible for long-duration treatment and which types are better matched for more traditional approaches.  This editorially independent podcast is supported with advertising.

Changes to the uveitis treatment landscape after years of stagnation warrant a reset on what is approved, what the latest data are, and which developments are in the pipeline. Glenn Jaffe, MD, summarized his state of the union on uveitis therapy, reviewing data from the most recently approved innovations in the field. Nicole Koulisis, MD, joins the program to review data on ocular injuries linked to social unrest in the summer of 2020. What were the causes linked to ocular injuries, how severely was vision affected, and what were final outcomes for these patients? This editorially independent podcast is supported with advertising.

In the first of this three-part series reviewing topics in wet AMD, Carl Regillo, MD, and Adrienne Scott, MD, join moderator John Kitchens, MD, to submit a pair of real-world patient cases illustrating how the need to reduce the burden of care may drive treatment decisions in patients with wet AMD. After they reveal how they managed their respective patient cases, Drs. Regillo and Scott join Dr. Kitchens for a review of how the latest innovations in retina could improve patients’ lives by alleviating treatment burden. This editorially independent podcast is supported with advertising.

As more data are published regarding medical intervention for macular hole closure, retina specialists want to know which patients are best suited for this approach and in which cases it may be most effective. Christina Weng, MD, MBA, invites Brian Do, MD; Mrinali Gupta, MD; and Dimitra Skondra, MD, PhD, to summarize and respond to a pair of retrospective case series that explored the safety and efficacy of drop regimens for macular hole closure. The group discusses the papers’ findings and comments on their own experience with medical management of macular holes.   This editorially independent podcast is supported with advertising.

In this roundtable moderated by Allen C. Ho, MD, IRD experts discuss their experiences treating patients with voretigene neparvovec (Luxturna, Spark), tips and tricks for subretinal delivery, and the nuances of genetic testing. Participants include Mark E. Pennesi, MD, PhD; Jacque L. Duncan, MD; Andreas Lauer, MD; Aaron Nagiel, MD, PhD; and Artur V. Cideciyan, PhD. To read the article, click here.  This podcast is editorially independent.

Extending treatment duration in patients with DME whose disease is responsive to steroid therapy could be instrumental in ensuring that visual disruption is kept at a minimum. How might the 3-year results from the PALADIN study guide treatment in the near future? Michael Singer, MD, reviewed data from a phase 4, 3-year, real-world study of patients whose DME was managed with fluocinolone acetonide 0.19 mg implant (Iluvien, Alimera Sciences). And NRR sat down with R.V. Paul Chan, MD, MSc, MBA, who summarized updates to ROP therapy as outlined in the 3rd edition of the International Classification of Retinopathy of Prematurity. What are the updates, and what spurred the ICROP to make them? Tune in to find out.  This editorially independent podcast is supported with advertising.

 Is a technology that inhibits tyrosine kinase and shows activity against all isoforms of VEGF and placental growth factor the future of wet AMD therapy? Data from the DAVIO study, which were shared at the 2021 AAO Annual meeting late-breakers session, could be of interest. David Boyer, MD, discussed the drug design of EYP-1901 (EyePoint Pharmaceuticals) and summarized the findings of the phase 1 DAVIO study, which examined the drug’s use in wet AMD patients. NRR also invited Firas Rahhal, MD, to review the safety and efficacy findings of the phase 3 NORSE-2 trial, which explored use of an ocular formation of bevacizumab (bevacizumab-vikg, Outlook Therapeutics) in patients with wet AMD.  This editorially independent podcast is supported with advertising.

The biosimilars are coming—and studies about them are starting to fill the literature. One such study is the COLUMBUS-AMD study, which evaluated the clinical equivalence of FYB201 to ranibizumab for the treatment of wet AMD. Aleksandra Rachitskaya, MD, breaks down the study with Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD. The group expands on what biosimilars are and asks what the future of retina could look like if biosimilars are approved for clinical use.  This editorially independent podcast is supported with advertising.

Can anti-VEGF agents act as effective prophylactic treatment for diabetic patients with a high risk of developing diabetic eye disease? Data from the Protocol W’s 2-year timepoint shared at the 2021 AAO Annual meeting might provide some answers on that question. Raj Maturi, MD, joined New Retina Radio to discuss his podium presentation on the topic.  New Retina Radio also invited Usha Chakravarthy, MD, PhD, to the program to outline her presentation on the secondary endpoints of the EDNA study. What was found when a team closely monitored patients for progression of unilateral to bilateral wet AMD? Join us on this episode to hear the details from these two presentations.  This editorially independent podcast is supported with advertising.

Knowing at which point in the course of disease progression a drug for geographic atrophy could be most effective may be key to unlocking a treatment paradigm if a drug is approved. What late-breaking data presented at the 2021 AAO annual meeting could help inform retina’s eventual strategy to treat GA?  New Retina Radio spoke with David Lally, MD, about his presentation on a post hoc analysis of the GATHER1 study to learn more about how GA patients who received avacincaptad pegol (Zimura, IVERIC bio) progressed from nascent disease to more advanced disease.  We also heard from Veeral Sheth, MD, MBA, about the phase 2b ALTISSIMO study, which explored the use of GB-102 (Graybug Vision) for the treatment of wet AMD. Just how long might a drug administered only twice a year provide relief to wet AMD patients? Stay with us to find out.  This editorially independent podcast is supported with advertising.

The treatment landscape for nAMD has expanded to include a refillable, intraocular device that continuously delivers therapy. What was the inspiration behind this new treatment approach? John Kitchens, MD is joined by inventor Eugene de Juan, MD and physician-scientist Tony Adamis, MD to discuss the device and the innovative technology behind its development. During this podcast, they reflect on how their careers and contributions from others in the field led to the drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

How do the latest data and treatment guidelines inform treatment strategies for retinopathy of prematurity (ROP) among European and Latin American retina specialists? Moderator Prof. Andreas Stahl (Germany) and panelist Dr. Maria Ana Martinez-Castellanos (Mexico) discuss the dynamics of patient care in their respective regions, and are joined by Silke Mader from the European Foundation for the Care of Newborn Infants to hear about the organization’s initiatives related to ROP. This editorially independent podcast is supported with advertising.

In part 2 of this special podcast interview with John W. Kitchens, MD, and Kirk Packo, MD, FACS, they dive into Dr. Packo's involvement in the creation of AAO subspecialty day, his passion for honoring the history of retina, and his assistance in advocating for vitreoretinal surgery improvements.  This podcast is editorially independent.